| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/1947601911408080 |
| P953 | full work available at URL | https://doi.org/10.1177/1947601911408080 |
| https://europepmc.org/articles/PMC3128636 | ||
| https://europepmc.org/articles/PMC3128636?pdf=render | ||
| https://journals.sagepub.com/doi/pdf/10.1177/1947601911408080 | ||
| P932 | PMC publication ID | 3128636 |
| P698 | PubMed publication ID | 21779503 |
| P5875 | ResearchGate publication ID | 51511933 |
| P2093 | author name string | Joerg Heyer | |
| Rónán C. O'Hagan | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice | Q71803596 | ||
| Cancer. Improved mouse models | Q73808101 | ||
| Ras pathway signals are required for notch-mediated oncogenesis | Q74298005 | ||
| Array comparative genome hybridization for tumor classification and gene discovery in mouse models of malignant melanoma | Q79074192 | ||
| Molecular pathogenesis of pancreatic cancer | Q79120111 | ||
| Insights from transgenic mouse models of ERBB2-induced breast cancer | Q80188238 | ||
| Kras and Hras--what is the difference? | Q82081792 | ||
| Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas | Q82297408 | ||
| Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas | Q24299520 | ||
| Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer | Q24528253 | ||
| Notch signaling controls multiple steps of pancreatic differentiation | Q24569636 | ||
| Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses | Q24630068 | ||
| Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach | Q24633776 | ||
| The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website | Q24645514 | ||
| A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene | Q24647664 | ||
| Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain | Q24794765 | ||
| EGFR mutation and resistance of non-small-cell lung cancer to gefitinib | Q27824829 | ||
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers | Q27851457 | ||
| Targeting RAS signalling pathways in cancer therapy | Q28201363 | ||
| Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche | Q28239639 | ||
| Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer | Q28271324 | ||
| Cancer genes and the pathways they control | Q28275089 | ||
| Crypt stem cells as the cells-of-origin of intestinal cancer | Q28304418 | ||
| Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes | Q28343950 | ||
| Notch signalling controls pancreatic cell differentiation | Q28504686 | ||
| ras oncogenes in human cancer: a review | Q29547769 | ||
| PI3K pathway alterations in cancer: variations on a theme | Q29615530 | ||
| Principles of cancer therapy: oncogene and non-oncogene addiction | Q29616779 | ||
| Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice | Q29617045 | ||
| Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 | ||
| Essential role for oncogenic Ras in tumour maintenance | Q30150290 | ||
| Genetic signatures of high- and low-risk aberrant crypt foci in a mouse model of sporadic colon cancer | Q31113039 | ||
| Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice. | Q37159280 | ||
| Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors | Q37177594 | ||
| Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions | Q37209222 | ||
| HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors | Q37325230 | ||
| Reconstruction of functionally normal and malignant human breast tissues in mice | Q37415657 | ||
| Targeting Notch signaling in pancreatic cancer patients--rationale for new therapy. | Q37598478 | ||
| Pharmacogenetics of breast cancer therapies | Q37633176 | ||
| Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer | Q37633765 | ||
| Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer | Q39076225 | ||
| Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells | Q39843809 | ||
| Finding and drugging the vulnerabilities of RAS-dependent cancers | Q39843813 | ||
| A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival | Q39845869 | ||
| Braf(V600E) cooperates with Pten loss to induce metastatic melanoma | Q39873596 | ||
| Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma | Q39885220 | ||
| Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion | Q40014102 | ||
| The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. | Q40110348 | ||
| Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients | Q40338985 | ||
| Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras | Q40424687 | ||
| Somatic activation of the K-ras oncogene causes early onset lung cancer in mice | Q40809826 | ||
| Notch and Kras in pancreatic cancer: at the crossroads of mutation, differentiation and signaling | Q41858645 | ||
| A novel splice variant of HER2 with increased transformation activity | Q42824817 | ||
| Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models | Q43056152 | ||
| De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor model | Q43244786 | ||
| Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development | Q43512505 | ||
| Germ-line HER-2 variant and breast cancer risk by stage of disease | Q43814381 | ||
| Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis | Q44259982 | ||
| Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. | Q44590619 | ||
| Oncogenic K-ras in mouse models of myeloproliferative disease and acute myeloid leukemia | Q44799859 | ||
| Direct sequencing analysis of transmembrane region of human Neu gene by polymerase chain reaction | Q45227766 | ||
| HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice | Q45654401 | ||
| Loss of heterozygosity in normal tissue adjacent to breast carcinomas. | Q45975916 | ||
| CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis | Q46492957 | ||
| Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib | Q46618741 | ||
| Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. | Q47745236 | ||
| Notch signaling: where pancreatic cancer and differentiation meet? | Q51747631 | ||
| Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis | Q52567811 | ||
| Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes | Q70641455 | ||
| Altered gene products are associated with activation of cellular rasK genes in human lung and colon carcinomas | Q71661782 | ||
| Field cancerization, clonality, and epithelial stem cells: the spread of mutated clones in epithelial sheets | Q33643333 | ||
| Mouse models for colorectal cancer | Q33739279 | ||
| Flipping the oncogene switch: illumination of tumor maintenance and regression | Q33870775 | ||
| Transgenic mouse models of human breast cancer | Q34130558 | ||
| Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo | Q34163139 | ||
| Unraveling human cancer in the mouse: recent refinements to modeling and analysis | Q34188976 | ||
| The genetics of pancreatic adenocarcinoma: a roadmap for a mouse model | Q34283792 | ||
| A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. | Q34549151 | ||
| Genetics and biology of pancreatic ductal adenocarcinoma. | Q34567515 | ||
| STI571 (Gleevec) as a paradigm for cancer therapy | Q34583847 | ||
| Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse | Q34596182 | ||
| Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras | Q34620985 | ||
| Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma | Q34642090 | ||
| Use of human tissue to assess the oncogenic activity of melanoma-associated mutations | Q34716087 | ||
| Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras | Q34763792 | ||
| Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer | Q34778936 | ||
| Pancreatic cancer biology and genetics | Q35013204 | ||
| The genetics of malignant melanoma: lessons from mouse and man. | Q35190150 | ||
| Farnesyl transferase inhibitors for patients with lung cancer | Q35817540 | ||
| Minireview: transcriptional regulation in pancreatic development | Q35986764 | ||
| Gefitinib in non-small cell lung cancer | Q36161284 | ||
| Wild-type NRas and KRas perform distinct functions during transformation | Q36176614 | ||
| The love-hate relationship between Ras and Notch. | Q36231474 | ||
| K-ras as a target for cancer therapy | Q36248002 | ||
| Advances in malignant melanoma: genetic insights from mouse and man. | Q36251116 | ||
| Geographic variation in the second-line treatment of non-small cell lung cancer | Q36394042 | ||
| Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon | Q36697241 | ||
| Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients | Q36755257 | ||
| Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer | Q36839754 | ||
| Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia | Q36980230 | ||
| The status and role of ErbB receptors in human cancer. | Q37086390 | ||
| Igf1r as a therapeutic target in a mouse model of basal-like breast cancer | Q37114859 | ||
| Kras regulatory elements and exon 4A determine mutation specificity in lung cancer | Q37126064 | ||
| Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice | Q37143762 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 335-343 | |
| P577 | publication date | 2011-03-01 | |
| P1433 | published in | Genes & Cancer | Q26842471 |
| P1476 | title | KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations | |
| P478 | volume | 2 |
| Q35680216 | A Genetic Porcine Model of Cancer |
| Q55263970 | CRISPR/Cas9: the Jedi against the dark empire of diseases. |
| Q48026385 | Conditional expression of Ki-RasG12V in the mammary epithelium of transgenic mice induces estrogen receptor alpha (ERα)-positive adenocarcinoma |
| Q37706853 | Gedunin inhibits pancreatic cancer by altering sonic hedgehog signaling pathway |
| Q38866525 | Generation of a MLL-AF9-specific stem cell model of acute monocytic leukemia |
| Q40968374 | Independent and core pathways in oncogenic KRAS signaling |
| Q41418283 | Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. |
| Q64119426 | Multifactorial Contribution of Notch Signaling in Head and Neck Squamous Cell Carcinoma |
| Q37660073 | Tumor suppressor role of phospholipase C epsilon in Ras-triggered cancers |
| Q53223303 | Viable pigs with a conditionally-activated oncogenic KRAS mutation |
| Q92783226 | Wnt Signaling Pathways in Keratinocyte Carcinomas |
Search more.